(Feb 9): Novo Nordisk A/S shares reversed some of last week’s plunge after Hims & Hers Health Inc pulled a copycat version of the new Wegovy weight-loss pill following US government threats to crack down on knockoffs. Hims & Hers backing down “gives Novo a reprieve from the compounded Wegovy pill and may help Novo’s efforts to limit the impact of injectable compounded Wegovy in the future,” Graham Parry, an analyst at Citi, wrote in a note. Pill launchAnalysts had hailed the new Wegovy pill as one of the most successful drug launches in recent years — a badly needed win for the Danish company. Along with compounders, competition between Novo and Lilly and pressure from the Trump administration have seen weight-loss drugs become cheaper, squeezing profit margins. The makers of blockbuster GLP-1 drugs, Novo and Lilly, have long complained the FDA hasn’t done enough to stop the proliferation of cheap, compounded weight-loss drugs.

Source: The Edge Markets February 09, 2026 11:48 UTC